NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 86 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $401,677 | +1.7% | 483,948 | -14.3% | 0.00% | – |
Q1 2023 | $395,133 | +26.4% | 564,475 | -8.1% | 0.00% | – |
Q4 2022 | $312,497 | -45.1% | 613,942 | -31.0% | 0.00% | – |
Q3 2022 | $569,000 | -39.3% | 889,298 | -2.4% | 0.00% | – |
Q2 2022 | $938,000 | -80.5% | 910,832 | -64.4% | 0.00% | – |
Q1 2022 | $4,810,000 | -61.7% | 2,558,479 | -1.8% | 0.00% | – |
Q4 2021 | $12,555,000 | -34.9% | 2,604,645 | -2.4% | 0.00% | -100.0% |
Q3 2021 | $19,299,000 | -20.8% | 2,669,276 | +1.2% | 0.00% | 0.0% |
Q2 2021 | $24,358,000 | -27.0% | 2,638,758 | -2.6% | 0.00% | 0.0% |
Q1 2021 | $33,358,000 | -11.9% | 2,709,825 | +0.9% | 0.00% | 0.0% |
Q4 2020 | $37,857,000 | +40.8% | 2,684,910 | +19.8% | 0.00% | 0.0% |
Q3 2020 | $26,885,000 | -26.0% | 2,240,550 | +2.4% | 0.00% | 0.0% |
Q2 2020 | $36,310,000 | +425.6% | 2,187,273 | +260.3% | 0.00% | – |
Q1 2020 | $6,908,000 | -7.5% | 607,032 | +0.1% | 0.00% | – |
Q4 2019 | $7,472,000 | +746.2% | 606,462 | +95.7% | 0.00% | – |
Q3 2019 | $883,000 | – | 309,840 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 1,156,200 | $10,672,000 | 1.77% |
ACT CAPITAL MANAGEMENT, LLC | 239,000 | $2,207,000 | 1.13% |
EcoR1 Capital, LLC | 2,358,804 | $21,772,000 | 0.81% |
Redmile Group, LLC | 3,919,235 | $36,175,000 | 0.54% |
Boxer Capital, LLC | 1,501,058 | $13,855,000 | 0.49% |
Baker Brothers Advisors | 3,821,740 | $35,275,000 | 0.16% |
Sio Capital Management, LLC | 38,312 | $354,000 | 0.09% |
Highland Private Wealth Management | 46,999 | $434,000 | 0.06% |
PERSONAL CFO SOLUTIONS, LLC | 23,710 | $219,000 | 0.04% |
Point72 Asset Management, L.P. | 883,102 | $8,151,000 | 0.04% |